Global (United States, European Union and China) At-Home Drug of Abuse Market Research Report 2019-2025

2 Global At-Home Drug of Abuse Quarterly Market Size Analysis

• 2.1 At-Home Drug of Abuse Business Impact Assessment - COVID-19
  • 2.1.1 Global At-Home Drug of Abuse Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
  • 2.1.2 Global At-Home Drug of Abuse Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global At-Home Drug of Abuse Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 Global At-Home Drug of Abuse Quarterly Market Size by Manufacturers, 2019 VS 2020
• 3.2 Global At-Home Drug of Abuse Factory Price by Manufacturers
• 3.3 Location of Key Manufacturers At-Home Drug of Abuse Manufacturing Factories and Area Served
• 3.4 Date of Key Manufacturers Enter into At-Home Drug of Abuse Market
• 3.5 Key Manufacturers At-Home Drug of Abuse Product Offered
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on At-Home Drug of Abuse Segments, By Type

• 4.1 Introduction
  • 1.4.1 Consumable
  • 1.4.2 Equipment
• 4.2 By Type, Global At-Home Drug of Abuse Market Size, 2019-2021
  • 4.2.1 By Type, Global At-Home Drug of Abuse Market Size by Type, 2020-2021
  • 4.2.2 By Type, Global At-Home Drug of Abuse Price, 2020-2021

5 Impact of Covid-19 on At-Home Drug of Abuse Segments, By Application

• 5.1 Overview
  • 5.5.1 Urine
  • 5.5.2 Saliva
  • 5.5.3 Hair
  • 5.5.4 Others
• 5.2 By Application, Global At-Home Drug of Abuse Market Size, 2019-2021
  • 5.2.1 By Application, Global At-Home Drug of Abuse Market Size by Application, 2019-2021
  • 5.2.2 By Application, Global At-Home Drug of Abuse Price, 2020-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Siemens AG
  • 7.1.1 Siemens AG Business Overview
  • 7.1.2 Siemens AG At-Home Drug of Abuse Quarterly Production and Revenue, 2020
  • 7.1.3 Siemens AG At-Home Drug of Abuse Product Introduction
  • 7.1.4 Siemens AG Response to COVID-19 and Related Developments
• 7.2 Danaher Corporation
  • 7.2.1 Danaher Corporation Business Overview
  • 7.2.2 Danaher Corporation At-Home Drug of Abuse Quarterly Production and Revenue, 2020
  • 7.2.3 Danaher Corporation At-Home Drug of Abuse Product Introduction
  • 7.2.4 Danaher Corporation Response to COVID-19 and Related Developments
• 7.3 Shimadzu Corporation
  • 7.3.1 Shimadzu Corporation Business Overview
  • 7.3.2 Shimadzu Corporation At-Home Drug of Abuse Quarterly Production and Revenue, 2020
  • 7.3.3 Shimadzu Corporation At-Home Drug of Abuse Product Introduction
  • 7.3.4 Shimadzu Corporation Response to COVID-19 and Related Developments
• 7.4 MilliporeSigma
  • 7.4.1 MilliporeSigma Business Overview
  • 7.4.2 MilliporeSigma At-Home Drug of Abuse Quarterly Production and Revenue, 2020
  • 7.4.3 MilliporeSigma At-Home Drug of Abuse Product Introduction
  • 7.4.4 MilliporeSigma Response to COVID-19 and Related Developments
• 7.5 Drägerwerk
  • 7.5.1 Drägerwerk Business Overview
  • 7.5.2 Drägerwerk At-Home Drug of Abuse Quarterly Production and Revenue, 2020
  • 7.5.3 Drägerwerk At-Home Drug of Abuse Product Introduction
  • 7.5.4 Drägerwerk Response to COVID-19 and Related Developments
• 7.6 Express Diagnostics
  • 7.6.1 Express Diagnostics Business Overview
  • 7.6.2 Express Diagnostics At-Home Drug of Abuse Quarterly Production and Revenue, 2020
  • 7.6.3 Express Diagnostics At-Home Drug of Abuse Product Introduction
  • 7.6.4 Express Diagnostics Response to COVID-19 and Related Developments
• 7.7 Psychemedics Corporation
  • 7.7.1 Psychemedics Corporation Business Overview
  • 7.7.2 Psychemedics Corporation At-Home Drug of Abuse Quarterly Production and Revenue, 2020
  • 7.7.3 Psychemedics Corporation At-Home Drug of Abuse Product Introduction
  • 7.7.4 Psychemedics Corporation Response to COVID-19 and Related Developments
• 7.8 Waters Corporation
  • 7.8.1 Waters Corporation Business Overview
  • 7.8.2 Waters Corporation At-Home Drug of Abuse Quarterly Production and Revenue, 2020
  • 7.8.3 Waters Corporation At-Home Drug of Abuse Product Introduction
  • 7.8.4 Waters Corporation Response to COVID-19 and Related Developments
• 7.9 BioMerieux
  • 7.9.1 BioMerieux Business Overview
  • 7.9.2 BioMerieux At-Home Drug of Abuse Quarterly Production and Revenue, 2020
  • 7.9.3 BioMerieux At-Home Drug of Abuse Product Introduction
  • 7.9.4 BioMerieux Response to COVID-19 and Related Developments
• 7.10 Roche
  • 7.10.1 Roche Business Overview
  • 7.10.2 Roche At-Home Drug of Abuse Quarterly Production and Revenue, 2020
  • 7.10.3 Roche At-Home Drug of Abuse Product Introduction
  • 7.10.4 Roche Response to COVID-19 and Related Developments

8 Supply Chain and Sales Channels Analysis

• 8.1 At-Home Drug of Abuse Supply Chain Analysis
  • 8.1.1 At-Home Drug of Abuse Supply Chain Analysis
  • 8.1.2 Covid-19 Impact on At-Home Drug of Abuse Supply Chain
• 8.2 Distribution Channels Analysis
  • 8.2.1 At-Home Drug of Abuse Distribution Channels
  • 8.2.2 Covid-19 Impact on At-Home Drug of Abuse Distribution Channels
  • 8.2.3 At-Home Drug of Abuse Distributors
• 8.3 At-Home Drug of Abuse Customers

9 Key Findings

10 Appendix

• 10.1 About Us